Valbiotis SA (FR:ALVAL) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Valbiotis SA, a French lab specializing in dietary supplements for metabolic and cardiovascular health, has been selected to present its Phase II/III clinical study results of TOTUM•63 at the prestigious EASD congress in 2024. The study showcases TOTUM•63’s effectiveness against prediabetes and type 2 diabetes, marking a significant innovation in non-drug treatments. Additionally, Valbiotis has begun preliminary discussions for international marketing partnerships.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue